A united states (us) customer contacted a siemens customer care center (ccc) to report an elevated atellica im folate (fol) result that was considered discordant with the repeat result.The customer processed the serum sample using the folate rbc assay instead of the folate serum assay on the atellica im 1300 analyzer.The quality controls (qc) were in range at the time of the event.A siemens technical application specialist (tas) went to the customer's site.During the visit, the tas assisted the customer in deactivating fol (fol rbc) assay and adding the fol serum assay.The reagents were calibrated, and qc was run successfully.The sample was repeated, and the repeat result was reported to the physician(s), as the correct result.The interpretation of results section of the atellica im folate (fol) instructions for use states: "results of this assay should always be interpreted in conjunction with patient's medical history, clinical presentation and other findings." siemens healthcare diagnostics is investigating.
|
Mdr 1219913-2022-00365 was filed on 2022-10-28 reporting an elevated result compared to repeat testing.A united states (us) customer contacted a siemens customer care center (ccc) to report an elevated atellica im folate (fol) result that was considered discordant with the repeat result.Additional information: 2023-01-09.Siemens reviewed the information and determined that factors such as pre-analytical factors and/or a sample handling/ stability issue cannot be ruled out as the cause of the elevated result.Internal siemens investigation indicates that the instrument and reagents were performing acceptably.The customer is operational.In section h6, the investigation finding, and investigation conclusion codes were updated.
|